Department of Microbiology, Kyungpook National University School of Medicine, #101, Dongin-dong-2 ga, Jung-gu, Daegu 700-422, Republic of Korea.
Int J Antimicrob Agents. 2010 Jan;35(1):76-9. doi: 10.1016/j.ijantimicag.2009.08.003. Epub 2009 Sep 24.
Mutations in DNA gyrase and topoisomerase IV genes are the main mechanisms of resistance to quinolones. In this study, we determined mutations in gyrA, gyrB, parC and parE among 57 ciprofloxacin-resistant Escherichia coli isolates from a South Korean hospital and analysed the relationship between the minimal inhibitory concentrations (MICs) of fluoroquinolones and mutations in the topoisomerase IV gene. All ciprofloxacin-resistant E. coli isolates carried double mutations in gyrA and at least a single mutation in parC; some isolates also carried a single mutation in parE. The most common mutations were S83L and D87N in gyrA, S80I in parC and S458A in parE, which accounted for 25% of isolates. Single mutations in parE at L445I, S458P and S458W were identified for the first time. Double mutations in parC and a combination of single mutations in parC and parE significantly increased the MIC values of fluoroquinolones. In vitro induction of resistance to ciprofloxacin showed that double mutations in gyrA were a prerequisite to conferring a resistant phenotype to fluoroquinolones, and an additional mutation in the topoisomerase IV gene increased the MIC values of ciprofloxacin. In conclusion, emergence of a new mutation in parC and parE and its accumulation induces high levels of resistance to fluoroquinolones in E. coli.
DNA 回旋酶和拓扑异构酶 IV 基因突变是喹诺酮类药物耐药的主要机制。在这项研究中,我们确定了韩国一家医院的 57 株环丙沙星耐药大肠杆菌中 gyrA、gyrB、parC 和 parE 基因的突变,并分析了拓扑异构酶 IV 基因突变与氟喹诺酮类药物最小抑菌浓度(MIC)之间的关系。所有环丙沙星耐药的大肠杆菌分离株均在 gyrA 中携带双重突变,至少在 parC 中有一个单一突变;一些分离株还携带 parE 的单一突变。最常见的突变是 gyrA 中的 S83L 和 D87N、parC 中的 S80I 和 parE 中的 S458A,占分离株的 25%。首次在 parE 中发现了 L445I、S458P 和 S458W 的单一突变。parC 中的双重突变和 parC 和 parE 中的单一突变的组合显著增加了氟喹诺酮类药物的 MIC 值。体外诱导对环丙沙星的耐药性表明,gyrA 中的双重突变是赋予氟喹诺酮类药物耐药表型的先决条件,拓扑异构酶 IV 基因中的额外突变增加了环丙沙星的 MIC 值。总之,parC 和 parE 中新突变的出现及其积累导致大肠杆菌对氟喹诺酮类药物的高水平耐药。